Identifiez-vous pour voir le profil complet de Basile
Bon retour parmi nous
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
ou
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
Paris, Île-de-France, France
Coordonnées
Identifiez-vous pour voir le profil complet de Basile
Bon retour parmi nous
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
ou
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
2 k abonnés
+ de 500 relations
Identifiez-vous pour voir le profil complet de Basile
Bon retour parmi nous
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
ou
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
Voir les relations en commun avec Basile
Bon retour parmi nous
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
ou
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
Voir les relations en commun avec Basile
Bon retour parmi nous
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
ou
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
Identifiez-vous pour voir le profil complet de Basile
Bon retour parmi nous
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
ou
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
Expérience et formation
-
SERB Pharmaceuticals
**** ** ********** ******* ******, ****** **** & ****** (****)
-
** *************** ***
********** ******* & ****** ****** **** *** ****** *** *******
-
********* ******
********* ******** *********
-
******** **
****** * (**) ******** *********
-
-
*********
********* ** **************** ** ********** ** ************* ************* ***** ** **é*******
-
Voir toute l’expérience de Basile
Découvrez son poste, son ancienneté et plus encore.
Bon retour parmi nous
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
ou
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Langues
-
Français
-
-
Anglais
-
-
Allemand
-
Voir le profil complet de Basile
S’identifier
Tenez-vous au courant des évolutions de votre monde professionnel
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
Autres profils similaires
-
Christine Truchi
Directrice accès au marché et relations institutionnelles chez Jazz Pharmaceuticals
ParisSe connecter -
Anne-Sophie JEAN
Senior Country Medical Director chez Jazz Pharmaceuticals France
Lyon et périphérieSe connecter -
Guillaume MABY
Regional Brand Lead
FranceSe connecter -
Magalie PEREZ
Pharmacien responsable - Directeur des affaires pharmaceutiques
Lyon et périphérieSe connecter -
Sylvain Ronceray
Business Unit Head Onco-Hematology at Jazz Pharmaceuticals
LyonSe connecter -
Alexandre von Lowis
ParisSe connecter -
Mickael Halimi
Associate Partner at Nextep
ParisSe connecter -
Pierre-Frederic Degon
Director, Government Affairs - Abbott France - Président APIDIM
Paris et périphérieSe connecter -
vincent olivier
Dirigeant de Recto Verso, société de conseil Santé en communication, stratégie et management
ParisSe connecter -
Rafal Jablonski
Key Account Manager w SERB Specialty Pharmaceuticals
Łódź et périphérieSe connecter -
Soukaïna Boughaba
International Brand Manager
ParisSe connecter -
Julie Assedo
Responsable affaires gouvernementales
ParisSe connecter -
Franck Cousserans
LyonSe connecter -
Francois Xavier d'Aillieres
Paris et périphérieSe connecter -
Antoine Bernasconi
Paris et périphérieSe connecter -
Philippe Maugendre
Directeur des Politiques Publiques - Affaires publiques & Gouvernementales - Sanofi
ParisSe connecter -
Caroline Blanc-Gatty
FranceSe connecter -
Antoine Vincent
Head of Europe - Commercial Operations at SERB Pharmaceuticals
Paris et périphérieSe connecter -
Claire Lhériteau-Calmé
Director, Public Affairs & Communications | Member of the Executive Committee France
AngersSe connecter -
Louison Lérein
Director, Public Affairs & Government Relations - FTI Consulting
ParisSe connecter
Découvrir plus de posts
-
Lend-Rx Technology
Today 12 June 2024, 5:50 PM CEST, join us at the SciLab Demoday2024 a Pharma Industry case study: Fertilizing social media posts with domain specific knowledge to improve data accuracy In this event, you'll learn how to: 👉 Get accurate et up to date picture of Therapeutics competition with no effort 👉 Find trends, topics and sentiment, easily 👉 Segment Healthcare Professionals influencer with high level of granularity https://lnkd.in/ezRgyP6n #SocialListening #AudienceIntelligence #SocialIntelligence #InfluencerAnalysis https://lnkd.in/e5Kqzqxk
-
Stephane Tholander
🌍 Exciting times ahead for digital health in France! I had the honor of speaking at the roundtable on "Digital Medical Devices: Where do we stand in their assessment and what healthtech stakeholders need to know?" organized by the Agence de l'innovation en santé (Lise ALTER, Camille Schurtz 👏 ) at the "Next generation of clinical research" event in Lille. The discussion was rich with insights on the current landscape of research and the future of digital therapeutics in France, especially. Special thanks to our moderator, Line FARAH (Ministère de la Santé), and my fellow speakers: Jérôme Fabiano (EIT Health France), Corinne Collignon (Haute Autorité de Santé), Sarah Zohar (INSERM), Dr. Joris Giai (CHU Grenoble Alpes) and Louisa Stüwe (Ministère de la Santé). 💡 One of the key insights: YES, foreign clinical data can be used to apply for reimbursed of a digital medical device in France! Let's connect and explore opportunities together! 🚀
93
1 commentaire -
Francois Xavier Dutrieux, PhD
A continuous success story for LumiraDx France teams in their action on outsourced medicine in French Hospitals! Whether to reduce waiting times or to better direct patients (and thus avoid contamination), delocalized biology is emerging as a key solution. Faced with this observation, LumiraDx automation systems have a future! By developing instruments that allow the screening or measurement of different biological markers such as viruses (flu, bronchiolitis, covid), pulmonary embolism, infections, but also for chronic pathologies (diabetes and heart failure). In French emergency services, their use is now authorized. For the past year, the GHEF (Grand Hôpital de l’Est Francilien), which has the largest emergency department in France, has equipped itself with automated machines on the 3 hospital sites. Well done ! Scottish Development International Ludovic Bal Caroline Pasquet Jean-Pierre Da Silva
31
1 commentaire -
Dr. Frank Grossmann
how brillant! At #OrphanHealthcare, we've just kicked open the doors to an new opportunity that's as big as the free pizza at a startup launch! We’re getting a new office at the end of summer and offering a great, still free 120 sqm of ultra-modern office space for your, absolutely amazing! And trust me, this isn't your average, everyday office space at the edge of Zurich. It combines work and work-life balance. 😍 Here’s the Scoop on the Space: 🖐🏻 If size Matters: A whopping 350 sqm of chic, open-plan office space begging you to throw some desks and dreams into it. And 120 sqm are still available for you. 🛀🏻 Design & Comfort: It’s got everything – 2 snazzy meeting rooms for when you need to impress, a lounge for lounging (obviously), an open kitchen to test your cooking show fantasies, and even an event spot for your TEDx rehearsal. 🤓 Tech Ready: All the state-of-the-art fixings to make sure you can tweet faster, work smarter, and Netflix chill harder. ⛳ Location, Location, Location: Right on the nerve center of everything cool - next to trams, trains, and an expressway to pretty much everywhere. 🚀 Why You’ll Love It: Price Tag. It’s about amazing for the prices others pay in downtown Zurich. Flex Appeal. Mold it, shape it, and dance in it – make this space your own! Network Nirvana. Join a community of thinkers, leaders, and occasional coffee-sharing who are all on the path to greatness. 👥 Limited Edition! This isn’t a drill people, spaces like this don’t come by often and they don’t stay free for long. It’s time to level up your workplace vibe and get your team into something stellar. And 2 wonderful partners are on board: Q4BS GmbH and The Social Mall - Center for Social Quality Impact 📞 Ready to claim your space in our new corporate paradise? Hit us up at team@verein-fohc.org and let’s chat about making magic happen in our new office! #Sustainable #Campus! 🎈 #OfficeSpace #Workspace #ModernOffice #BusinessOpportunity #OfficeForRent #ProfessionalSpace #CollaborationSpace
3
2 commentaires -
Clean label supplements
[INNOVATION] SLEEP TIGHT Do you know that over one French person in three suffers from poor-quality sleep? According to a report from INSV Institut National du Sommeil et de la Vigilance, 8 out of 10 people say they suffer from night-time awakenings. Laboratoire PYC has developed a new food supplement formula with the delicate flavours of lemon and chamomile. Chamomile is a well-known plant used in supplements. It helps to maintain a healthy sleep and contributes to optimal relaxation. This supplement also contains melatonin which contributes to the reduction of time taken to fall asleep. Furthermore, SLEEP TIGHT provides magnesium and vitamin B6 to help reducing fatigue. Laboratoire PYC is a French manufacturer of food supplements 🇫🇷. Discover its expertise through its boxed set of 10 innovative, clean-label formulas: https://lnkd.in/dKXbce4Y To request samples : https://lnkd.in/dMv9qui LABORATOIRE PYC by Solina - Your industrial partner in nutritional solutions #innovation #foodsupplement #madeinfrance🇫🇷 #sleep #cleanlabel Solina
1
-
Neil Grubert
A relaxation of evidentiary requirements for HTA in France in some circumstances is highlighted in the latest annual report of the Commission de la Transparence (CT; Transparency Committee). The proposed new approach “seeks to strike a balance between accelerated clinical development and level of uncertainty for the benefit of patients.” The CT notes that, “while the gold standard remains the randomised controlled trial (the safest design for patients), the Committee now accepts, under certain justified conditions, a reduction in the level of evidence required for reimbursement of health products, by valuing indirect comparisons subject to their methodological quality.” Specifically, “the results of a study without a comparator arm may now be accepted, subject to 3 essential conditions: ● Duly justified impossibility of evaluating the new drug in a comparative trial; ● Choice of external comparator decided upstream during the drafting of the study protocol provided and not adapted and determined on the basis of the results of the single-arm trial; ● Rigorous matching. Thus, indirect comparison data of good methodological quality or data from control groups are now acceptable, provided that they are explained and justified upstream by the manufacturer. Under the new policy, the CT evaluated a drug based on data from an indirect comparison and awarded an ASMR of IV. The annual report also discloses that the CT will use nuances in ASMR ratings to reflect uncertainties and thus better inform public decision makers: “When it comes to recommending the reimbursement of a new treatment, the Committee will continue to demand a rigorous methodology so that its opinions can always be qualified as scientific, indicating when it considers that the data are not sufficient to provide a complete picture. With this in mind, the new doctrine recognises that ASMR Vs may correspond to several types of situation, in particular, those where the absence of added value is proven and those where a development plan, with a timetable given to the manufacturer, could enable the uncertainty to be resolved.” #France #HTA #indirectcomparison
195
7 commentaires -
Nienke Feenstra
« In a world with increasing geopolitical tensions, we need to make sure that patients can get access to the treatments they need » one of the many reflections shared by our CEO Christophe Weber during his interview in « Les Echos ». He outlines the need for pharmaceutical companies to have scale and be global, how he transformed Takeda over the last decade, how exciting scientific and digital progress will impact health care systems. Health care systems in which Takeda wants to partner with all parties involved to ensure they stay sustainable. An ambition everyone in Takeda contributes to, to ensure a better health and a brighter future.
93
-
Isabelle M. Gorrillot
Today is election day round 2 in France. A recent post on LinkedIN stated that National Rally ("RN") voters were largely uneducated compared to those supporting the center and left, implying that stupidity and lack of analytical skills are on the right, and intelligence on the left. Is it? or is it that voters expect their government to fulfill its elementary duty of ensuring the safety and well-being of the entire population (vs. thugs and criminals). Case in point, touching close to home: a young man, "J.", hard worker, 21 years old, athletic, was brutally attacked by 3 guys on Friday night between 12.00 am and 2.00 am, in the vicinity of the Saumur townhall ("presided" by its leftist mayor). It was celebration night for many French soccer supporters, but for J. it may have been the night that changed his life for ever. Heliported in critical condition, he is in induced coma fighting for his life. Let's sink in that this happened in Saumur - 27000 inhabitants, beautiful small touristy town on the Loire - not Marseilles or the northern suburbs of Paris. unfortunately, this is not an extraordinary occurrence of violent crime in Saumur. So, whether educated or not, the expectation expressed by the people of France last week was to somehow see restoration of safety and justice for all (not just thugs and criminals). Reducing the voting pattern to wducation vs non-educated is flawed. What this alleged statistical analysis of voting patterns is that usually less educated people are also less well-off, with less access to safe environments and legal representation, thereby feeling more exposed to insecurity and violence than the supposedly "smart" ones voting on the left. However this small analytical detail is consistently obliterated by the alleged political analysts displayed on the main news channels. 50 years of judicial laxism have dug the grave of democracy and brought a program that together with promising to restore security also comprises other less palatable measures. Meanwhile, our young pal is fighting for his life and may never be able to run as he used to, nor work, contribute to the society, but instead require life-long medical care (with the price tag attached). https://lnkd.in/e8kRKf4w
4
-
Cecile Brosset Dubois
Today Sonio is reaching a new milestone towards improved access and quality of care for women and children worldwide: pending approval of the French Ministry of Economy, Sonio will join the Samsung Medison family! After 4 years of incredibly fast growth, building a unique product and above all things an exceptional team, this fantastic partnership will allow us to accelerate our roadmap, boost our commercial expansion globally and reaffirm our mission, while staying independent in our execution. I’m very excited about this new phase in Sonio’s life. Beyond the very strong technological and business rationale, this adventure is an opportunity to confirm our human and operational model at scale. I’m truly thankful to everyone who made this possible: 🙌 our incredibly driven team, who manages to combine excellence, humility, hard work and care - you so deserve this success! Get ready for this new ride together!! 🚀🚀 🙏 our investors, starting with our business angels, the first true believers Alain Decombe and all the funds after them Elaia, Bpifrance, OneRagtime, European Investment Bank (EIB), Cross-Border Impact Ventures - Annie Theriault thanks for being such a smart and committed partner, we are determined to pursue our mission and unfold our impact roadmap with your guidance🤰🏽 👩⚕️ our customers and clinical partners worldwide, who fed and validated our vision. We will continue to provide you with our device-agnostic AI-powered software solutions. We will keep our unprecedented clinical understanding of maternal and fetal medicine and ultrasound. We will preserve our agility and fast delivery to the benefit of physicians' workflow and patients outcomes Through this new success, I see the validation of an endeavor that goes beyond Sonio, the validation that there is a business model in healthtech and medical AI, that there is room for exceptional technology in health, that there is a huge women’s health market to address with deep unsolved pains, that the French Tech is unique, smart, fast and boiling with potential, that there is a way to become an entrepreneur after a career in the Corporate world (and vice-versa), that a woman, a mother, can and should shoot for the stars, it IS possible, you have to trust yourself!, that it’s ALL about the people you meet and trust along the way, in their diversity and humanity To my partners Remi Besson David Amouyal Deepak Prakash Dagmar Nuber THANK YOU! sooo excited to enter this new phase with you!!! Let’s keep building and having so much fun together! To the early founders Yves Ville Julien Stirnemann Emmanuel Spaggiari Stéphanie Allassonniere Erwan LE PENNEC thanks for trusting me To our advisors Sacha Loiseau Yann Fleureau Laurent Merlino, thank you for your invaluable guidance, it made such a difference Special thanks to my husband Arnaud Dubois - my first sponsor and mentor Can’t wait to kick start after closing YangKyu (YK) Kim, Kyu Tae Yoo, Mathieu Apotheker! 🚀
696
114 commentaires -
Innoviris
📢 Research Platform - Towards a healthcare society 🤝 Are you looking to conduct disruptive research on the topic of health? Health as a state of complete physical, mental and social well-being and not the absence of disease or other physical defects. Could this research be performed by an interinstitutional and multidisciplinary consortium of research organizations located in the Brussels-Capital Region? Is the medium-term objective of the project to valorize its results? Find out more about this program here 👇 https://bit.ly/3UM27Jj Deadline : 28 juin 2024 #wefundyourfuture #research #health #healthcare #brussels
6
-
Elizabeth Hunt
🚀 Elevate your expertise and ensure regulatory compliance with Cencora PharmaLex's educational resources on #Annex 1 #Annex 1 is a cornerstone of Good Manufacturing Practice (GMP), outlining crucial guidelines for sterile medicinal products. Understanding its intricacies is paramount for ensuring product quality and patient safety. Explore our educational and valuable content on #Annex 1: 1️⃣ Webinars: Listen to our on-demand webinar to delve into Annex 1 compliance, interpretations, and practical implementation strategies. Gain insights from Londa R. and Patrick Nieuwenhuizen. https://lnkd.in/e6B8gcjE 2️⃣ Articles & Blogs: Access recent articles and blogs offering best practices, and key takeaways from PDA - Parenteral Drug Association events related to #Annex 1 compliance. https://lnkd.in/enuXzbUa https://lnkd.in/ebyGgUfT https://lnkd.in/euYWBd7i 3️⃣ Podcast: Tune In: Explore Annex 1 Insights on Our Podcast! 🎧 https://lnkd.in/ejB-xFG8 4️⃣ Consultation Services: Connect with our experts Londa R. and Patrick Nieuwenhuizen - all you need to know about the EU GMP #Annex 1 regulation. Schedule your 1:1 today! https://lnkd.in/eK3MVhw2 Comply with #Annex 1 - Get in Touch With Us: https://lnkd.in/eG8hd2V5 #Annex1 #PharmaceuticalCompliance #GMP #Compliance
17
-
Paul Hudson
Important news to start the week: On the sidelines of President Macron’s “Choose France” summit, we are delighted to announce today a €1 billion+ investment that will expand the Sanofi industrial footprint for manufacturing innovative biomedicines in France. We are often quick to emphasize - rightly so - the invaluable role of scientists in discovering medical breakthroughs. But let’s not forget the integral role of manufacturing teams, who turn those discoveries into life-changing treatments for patients. That’s why, we’re matching the outstanding work done by our scientists in the labs with the construction of world-class bioproduction facilities. Today’s historic investment is the latest proof-point of our modernization. A modernization that is fundamental to achieving our collective ambition: transforming the practice of medicine for patients, in France and around the world. Read more: https://lnkd.in/gu3Ak7XM #science #innovation
2 914
46 commentaires -
Clever-Access
We previously discussed #QALYs in #HealthEconomicEvaluations ? But to calculate #QALYs, you need #utilities 😀 ! These are subjective values, and estimate the perception of #QualityOfLife at a certain point in time. This video describes the main methods to derive such estimates. #TTO #VAS #SG, #EQ5D, etc... these are key words you may have herd before. Wanna understand them better? Of note : all the links we share contain a summary PDF you can download, summarizing the video, so don't hesitate ! https://lnkd.in/e-7jxrfa
55
-
Sigal Shafran Tikva CCRN, MPH, MHA, PhD
"Adherence 2:0, New Approches" 💡 As an EntrepreNurse, I'm constantly seeking fresh perspectives and innovative approaches. Recently, I had the opportunity to lead a workshop about adherence and compliance in healthcare for physicians and nurses. It sparked a question: How can we adapt our strategies to the unique needs of different patient generations and the changing world we live in? Traditional methods might not resonate with patients today anymore. We need to explore innovative ways to engage patients in their treatment plans and to empower clinicians with new tools to collaborate with patients on improving adherence. The discussion was inspiring, and I'm excited to explore these possibilities further in our next sessions. #innovation #adhearance #complaince #nurses #physicians
82
12 commentaires -
Eric Merle
Outstanding “Demystifying AI Accross Industries” tonight organized by French Tech Boston in the beautiful Akeneo offices. Thank you Zena Sfeir Gehchan, Joseph Péteul (Cap8), Jonathan Baptista (DeepLife), Francois Silvain (NewEcom.ai), Laetitia Korn (Akeneo: The Product Experience Company), Jean Arnaud (N O V A) for an engaging panel and wonderful event. Here is what I took away from it: • The revolution is here • The promises are real • The responsibilities are key • Reliability of data is critical • AI can augment / enhance rather than replace • AI can enable new answers AND different ways of thinking Let’s embrace the power of data and continue to develop tools to extract better insights to impact lives: patients, consumers, employees, students and more! I am excited to see the #innovation that is taking place and look forward to more thought-provoking events from La French Tech Boston! #AI #TalkinBoutARevolution #FrenchTech #ArtificialIntelligence #Boston #PromptingIsTheNewBlack #LFG
21
4 commentaires -
Qiaoli VRINAT
Facing growing challenges like staff shortages, medication complexity, and the need for better care coordination, AI emerges as a promising solution. A recent study by Health&Tech Intelligence shows that In-House Pharmacies (PUIs) in France are at the forefront of AI adoption, developing innovative tools to address their specific service needs. #AI #artificialintelligence #healthcareAI #AIinhealthcare #hospitalpharmacy #patientsafety #HealthTechIntelligence #pharmaciehospitalière
3
-
Claire Biot
Thank you again #Nobel Prize Laureate Jean Tirole & Pierre Dubois for a thought-provoking Health Economics Conference at Toulouse School of Economics last month! ❣ Happy to share that the replay 📹 of our panel on the use of Health Data, Platforms & Digital Technologies for Innovation is now available 👇 The panel was chaired by Jean Tirole, with Edwin Morley-Fletcher & Ariel Dora Stern 👉 I was happy to present Dassault Systèmes' ambition in #LifeSciences & #Healthcare, and how #VirtualTwin can accelerate therapeutic innovation and improve medical practice. Among examples shared, I mentioned #SCA (synthetic control arms), #MediTwin, our partnership with FDA for in silico clinical trials. Edwin Morley-Fletcher shared the ambition of European Commission to build a common platform for Human Virtual Twins and the role played by #EDITH consortium to create standards. Ariel Dora Stern shared meaningful examples of the use of #AI and #GenAI in drug discovery as well as medical practice. The ⁉ Q&A ⁉ session was quite stimulating, thank you 🙏 to the passionate attendees in the audience! 🌩 Key challenges ahead of us include: 1️⃣ Access to data, which itself requires a solid business model, data standardization, trusted Cloud 2️⃣ Reimbursement & adoption in physicians workflow -> change management will be key
25
-
Célia Dorlhac
💪 We are very proud to have been included among the #key #startups in #digital #health who are helping to #combat #medical #deserts. Since CONCILIO's creation, we have been helping companies find solutions to support their employees' health in France and in more than 64 other countries. Our #unique #medical #concierge service offers : ✅ #Teleconsultation, 24/7, in five languages. ✅ #Digital #health #checkups focused on general health, women's health, mental health, and more. ✅ Daily support by #recommending #top #specialists endorsed by their peers to prevent medical wandering. ✅ #Medical #appointment #booking with general practitioners and specialists to save time and reduce the mental load for employees and their families, particularly those living in medical deserts. #digitalhealth #telemedecine #telehealth #bestdigitalhealthcompany #concilio #medicalconcierge
2
3 commentaires -
Hung Trinh
Sanofi Pfizer AstraZeneca Pledge Nearly $2.16B in Total Investments in #France Ahead of the French government’s annual Choose France economic summit, several pharmaceutical industry leaders have announced plans to pump a total of approximately $2.16 billion (€2 billion) in investments in the country, according to media reports. Sanofi on Monday announced that it would invest more than $1.08 billion (€1 billion) to boost its biomanufacturing capacity and improve France’s ability to “control the production of essential medicines,” according to its announcement. The investment follows a previous nearly $2.7 billion (€2 billion) commitment by the company in France “to support health sovereignty.” The bulk of the additional funding will go to the company’s site in Vitry-sur-Seine and will help construct a new facility to double the production of monoclonal antibodies at the location. The Vitry site will also potentially help Sanofi manufacture several biologic pipeline assets, including potential blockbusters for asthma, type 1 diabetes and multiple sclerosis. A smaller portion of Monday’s funding will go to Sanofi’s sites at Le Trait and Lyon Gerland, also to expand manufacturing capacity. Overall, the pharma expects its investment to create more than 500 new jobs. CEO Paul Hudson in a statement said that Sanofi has a “record number” of investigational medicines and vaccines with best-in-class potential, which could help the company respond to public health challenges. “With these unprecedented industrial investments, we remain true to our history by once again choosing France to produce these future medicines,” Hudson added. https://lnkd.in/eHwWjHgy
22
-
Duane Clark
Hello Rare Diseases Community We mark #FabryAwarenessMonth in April, an important milestone for the Fabry community. For those unfamiliar with the condition, Fabry is a rare disease that can impact many parts of the body including the kidneys, heart, brain and skin. At Sanofi, we believe in the power of knowledge, compassion, and collective action to make a meaningful impact on rare diseases like Fabry. Part of our mission is rooted in pursuing better care through early diagnosis, which plays a crucial role in managing Fabry disease, particularly in women. Women with Fabry may present with variable symptoms, leading to delays in treatment or misdiagnoses. By continuing to research Fabry disease and raising awareness among healthcare providers, we can facilitate early detection and access to suitable care. One such way we contribute to advancing understanding is through our Fabry Registry. Established in 2001, this registry tracks patient journeys, offering valuable insights into the disease's impact over time and its link to sex and genetics. Hear more about the diagnosis journey of the women in the Hill family in this video. Help us to spread awareness, ignite conversations, and amplify the impact of Fabry disease this month. Make sure to follow along on Sanofi’s corporate channels to learn more about how to get involved.
127
Autres personnes nommées Basile Gorin
1 autre personne nommée Basile Gorin est sur LinkedIn
Autres personnes nommées Basile Gorin